Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (1-10 of 303) with videos related to

Pageof 31
Sort By:
Oncology (Williston Park, N.Y.)|March 16, 2007
Recognizing and managing toxicities of molecular targeted therapies for colorectal cancerAxel Grothey
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
Optimizing systemic therapy selection in metastatic colorectal cancerAxel Grothey
Chinese Clinical Oncology|November 7, 2022
Pembrolizumab in metastatic mismatch repair deficient colorectal cancer: the beginning of a journey into the land of immunotherapies for all cancersAxel Grothey
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendationsAxel Grothey
Oncology (Williston Park, N.Y.)|March 16, 2010
Risk assessment in stage II colon cancer: to treat or not to treat?Axel Grothey
Seminars in Oncology|October 3, 2003
Oxaliplatin-safety profile: neurotoxicityAxel Grothey
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Biological therapy and other novel therapies in early-stage disease: are they appropriate?Axel Grothey
Clinical Advances in Hematology & Oncology : H&O|July 11, 2020
EGFR inhibition in colorectal cancer with liver metastasisAxel Grothey
Therapeutic Advances in Medical Oncology|July 27, 2011
Medical treatment of advanced colorectal cancer in 2009Axel Grothey
Clinical Advances in Hematology & Oncology : H&O|November 16, 2019
Management of patients with relapsed/refractory metastatic colorectal cancerAxel Grothey
Pageof 31

Showing results (1-10 of 303) with videos related to

Sort By:
Pageof 31
Oncology (Williston Park, N.Y.)|March 16, 2007
Recognizing and managing toxicities of molecular targeted therapies for colorectal cancerAxel Grothey
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
Optimizing systemic therapy selection in metastatic colorectal cancerAxel Grothey
Chinese Clinical Oncology|November 7, 2022
Pembrolizumab in metastatic mismatch repair deficient colorectal cancer: the beginning of a journey into the land of immunotherapies for all cancersAxel Grothey
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendationsAxel Grothey
Oncology (Williston Park, N.Y.)|March 16, 2010
Risk assessment in stage II colon cancer: to treat or not to treat?Axel Grothey
Seminars in Oncology|October 3, 2003
Oxaliplatin-safety profile: neurotoxicityAxel Grothey
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Biological therapy and other novel therapies in early-stage disease: are they appropriate?Axel Grothey
Clinical Advances in Hematology & Oncology : H&O|July 11, 2020
EGFR inhibition in colorectal cancer with liver metastasisAxel Grothey
Therapeutic Advances in Medical Oncology|July 27, 2011
Medical treatment of advanced colorectal cancer in 2009Axel Grothey
Clinical Advances in Hematology & Oncology : H&O|November 16, 2019
Management of patients with relapsed/refractory metastatic colorectal cancerAxel Grothey
Pageof 31